- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05039866
Long-Term Follow-up of Subjects Who Were Treated With ST-920
April 9, 2024 updated by: Sangamo Therapeutics
Long-Term Follow-up of Fabry Disease Subjects Who Were Treated With ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy
Long-term follow-up of subjects who received ST-920 in a previous trial (ST-920-201) and completed at least 52 weeks post-infusion follow-up in their primary protocol.
Enrolled subjects will be followed for a total of up to 5 years following ST-920 infusion.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with ST-920 in the clinical study ST-920-201.
All subjects dosed in the study who completed at least 52 weeks post-infusion follow-up in their primary protocol will be offered to participate.
Subjects who enroll will be monitored for a total of up to 5 years following ST-920 infusion.
Study Type
Observational
Enrollment (Estimated)
48
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Victoria
-
Parkville, Victoria, Australia, 3050
- The Royal Melbourne Hospital
-
-
-
-
-
Cambridge, United Kingdom, CB2 0QQ
- Addenbrooke's Hospital
-
-
-
-
California
-
Irvine, California, United States, 92697
- University of California, Irvine
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospital and Clinics
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota Medical Center
-
-
New York
-
New York, New York, United States, 10029
- Mt. Sinai Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Virginia
-
Fairfax, Virginia, United States, 22030
- Lysosomal & Rare Disorders Research & Treatment Center (LDRTC)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All subjects who have received ST-920 in separate parent trial and who have consented to participate in this Long Term Follow-up study.
Description
Inclusion Criteria:
- Subjects who received ST-920 therapy in a separate parent trial
- Subjects who have consented to participate in this LTFU study.
Exclusion Criteria:
-This study has no exclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Subjects who received ST-920
Subjects who received ST-920 in a separate parent trial
|
No study drug is administered in this study.
Subjects who received ST-920 in a separate parent trial will be evaluated in this trial for long-term safety.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate long-term safety of ST-920
Time Frame: 4 years
|
To evaluate long-term safety of ST-920 by assessment of incidence and severity of adverse events (AEs)
|
4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Monitor, Sangamo Therapeutics, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 16, 2021
Primary Completion (Estimated)
June 1, 2028
Study Completion (Estimated)
June 1, 2029
Study Registration Dates
First Submitted
August 20, 2021
First Submitted That Met QC Criteria
September 1, 2021
First Posted (Actual)
September 10, 2021
Study Record Updates
Last Update Posted (Actual)
April 10, 2024
Last Update Submitted That Met QC Criteria
April 9, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Lipid Metabolism Disorders
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Sphingolipidoses
- Lysosomal Storage Diseases, Nervous System
- Cerebral Small Vessel Diseases
- Lipidoses
- Lipid Metabolism, Inborn Errors
- Fabry Disease
Other Study ID Numbers
- ST-920-LT01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fabry Disease
-
CENTOGENE GmbH RostockCompletedFabry Disease | Anderson-Fabry Disease | Fabry´s DiseaseArgentina, Belgium, Croatia, Czechia, Denmark, France, Germany, United Kingdom
-
Wuerzburg University HospitalTakedaEnrolling by invitationLysosomal Storage Diseases | Fabry Disease | Fabry Disease, Cardiac Variant | HCM - Hypertrophic Cardiomyopathy | Anderson Fabry DiseaseGermany
-
University Hospital, RouenUnknownAnderson-Fabry DiseaseFrance
-
Amicus Therapeutics France SASActive, not recruitingFabry Disease | Anderson Fabry DiseaseFrance
-
Academisch Medisch Centrum - Universiteit van Amsterdam...RecruitingFabry Disease | Fabry Disease, Cardiac VariantNetherlands
-
Taipei Veterans General Hospital, TaiwanSanofiUnknownFabry Disease, Cardiac Variant
-
University of CambridgeSanofiRecruiting
-
Shaare Zedek Medical CenterJohannes Gutenberg University MainzCompleted
-
Wolfson Medical CenterUnknownFabry Disease in the Young StrokeIsrael
-
Lysosomal and Rare Disorders Research and Treatment...SanofiUnknown
Clinical Trials on ST-920
-
Sangamo TherapeuticsActive, not recruitingFabry DiseaseUnited States, United Kingdom, Taiwan, Australia, Germany, Italy, Canada
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAcute Ischemic Stroke
-
Luminary TherapeuticsNationwide ChildrenNot yet recruitingSystemic Lupus Erythematosus
-
Luminary TherapeuticsCase Comprehensive Cancer CenterRecruitingLymphoma, Non-Hodgkin Lymphoma, B-CellUnited States
-
Nanyang Technological UniversityActive, not recruitingPhysiological Outcomes of High-intensity Interval Training With Post-exercise Blood Flow RestrictionExercise PerformanceSingapore
-
Mashhad University of Medical SciencesCompletedAnxiety | Labor Pain
-
Abbott Medical DevicesTerminatedCoronary Artery DiseaseUnited States
-
Istituto Superiore di Osteopatia di MilanoCompletedHealthy | Osteopathic ManipulationItaly
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)RecruitingPeripheral NeuropathyUnited States
-
University Hospitals Coventry and Warwickshire...RecruitingNervous System Diseases | Neuromuscular Diseases | Respiratory Failure | Respiratory Insufficiency | Amyotrophic Lateral Sclerosis | Sleep-Disordered Breathing | Neuro-Degenerative Disease | Neuron Disease, MotorUnited Kingdom